Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Jomarien García

Jomarien García

Leiden University Medical Center , Netherlands

Title: Injectable thermosensitive hydrogel based on the physical mixing of Chitosan/Pluronic F127 as intraarticular drug delivery system

Biography

Biography: Jomarien García

Abstract

Knee osteoarthritis (OA) is a disease characterized mainly by cartilage degradation, which produce pain, stiffness, and loss of motion in the joint. Pharmacologycal therapy of this disorder is directed towards pain and inflammation. Non-steroidal and steroidal anti-inflammatory substances are the most frequently used agents. Nevertheless, the oral or systemic administration of such drugs is hindered by numerous side effects, which could be overcome by their intra-articular (IA) administration. The aim of this work was to evaluate the behavior of dexamethasone sodium phosphate (DMT) release from thermosensitive hydrogels based on the physical mixing of Chitosan/Pluronic F127 (CS/PF) as an IA drug delivery system. For the preparation of hydrogels, chitosan (1% w/v) and pluronic (20, 25, 30% w/v) were mixed. Formulation with 25% of pluronic (CS/PF-25) was selected for several assays. Scanning electron microscopy analysis indicated that the CS/PF-25 hydrogels exhibited a low porous structures. Infrared spectroscopy analysis indicated the main functional groups of each component of the hydrogel. The cytotoxicity and cell viability of the hydrogels were assessed by MTS and LIVE/DEAD® assays, where the results demonstrated non-cytotoxic effect of the hydrogel on the human chondrocyte cell culture (C-28). DMT was mixed with CS/PF-25 hydrogel at the concentration of 2 mg/mL concentration, in vitro release study showed that there is no initial burst of drug and 50% of DP was delivered in 72 hours. This study suggests the potential of CS/PF-25 gel as an injectable carrier for future applications of delivering therapeutics for the knee osteoarthritis treatment